Evidence map›Paper›PMID 40855419›Full record

SynthesisBMC neurology2025

Effect of Statin Therapy on Neurological Outcomes in Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis of 1464 Patients.

Abdelrahman Hafez, Ahmed Abdelaziz, Ibrahim Kamal, Ahmed Farid Gadelmawla, Rehab Adel Diab, Shrouk Ramadan, Mohamed Hatem Ellabban, Ahmed Elaraby, Karim Atta, Mohamed Mahmoud Gomaa and 8 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Abdelrahman HafezMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA. Abdelrahmanhafez13498@gmail.com.
Ahmed AbdelazizMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Ibrahim KamalMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Ahmed Farid GadelmawlaMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Rehab Adel DiabMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Shrouk RamadanMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Mohamed Hatem EllabbanMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Ahmed ElarabyMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Karim AttaMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Mohamed Mahmoud GomaaMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Mohamed AbdelazizMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Ahmed O SenaDepartment of Cardiovascular Medicine, Cairo University Hospitals, Cairo, Egypt.
Ahmed NasrMedical Research Group of Egypt (MRGE), Negida Academy, Arlington, MA, USA.
Mazen HassaninFaculty of Medicine, Cairo university, Cairo, Egypt.
Omar AbdelgawwadFaculty of Medicine, Mansoura university, Mansoura, Egypt.
Ahmed Almahdy MohamedDepartment of Medicine, Cardiovascular Division, University of Minnesota Twin Cities, Minneapolis, MN, USA.
Ahmed BahnasyHematology and Oncology Department, Mayo Clinic, Medicine, Scottsdale, AZ, USA.
Emad SingerUniversity of Texas MD Anderson, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition complicated by cerebral vasospasm and deterioration of neurological functions. Statins have been proven to reduce the incidence of vasospasm and limit the neurological deterioration with controversial data. We aimed to give a comprehensive assessment of statins in patients with aSAH.

methodsWe retrieved PubMed, Scopus, WOS, and the Cochrane library for RCTS assessing the efficacy of statins in patients with aSAH from inception to April 2024. Cerebral vasospasm and neurological deterioration were the primary efficacy outcomes of interest. Other secondary efficacy outcomes were delayed ischemic neurological deficits, and all-cause mortality. Safety outcomes were cerebral infarction, rhabdomyolysis, and elevated transaminase levels. STATA 18MP was used to analyze the data using a random-effect model.

resultsA total of nine RCTs comprising 1464 patients, with a mean follow-up of 6 months were included in the final analysis. After 2 weeks of administration, statins were associated with a lower risk of cerebral vasospasm (OR: 0.74, 95% CI: 0.57 to 0.96, p = 0.03; I

conclusionStatins were associated with reduced vasospasm with no notable improvement in neurological prognosis. However, the 2-week time window of statins is powered by small sample size, and further large-volume RCTs are warranted.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsSubarachnoid HemorrhageVasospasm, IntracranialHumansRandomized Controlled Trials as TopicTreatment OutcomeHydroxymethylglutaryl-CoA Reductase InhibitorsAneurysmal subarachnoid hemorrhageASAHCerebral vasospasmNeurological deterioration

Identifiers

PMID40855419
PMCPMC12376394

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.